<DOC>
	<DOCNO>NCT01340443</DOCNO>
	<brief_summary>This observational study evaluate safety efficacy MabThera/Rituxan ( rituximab ) plus chemotherapy first-line treatment patient diffuse large B-cell lymphoma ( DLBCL ) follicular lymphoma ( FL ) . Data collect patient 6 month induction treatment 3 year follow-up .</brief_summary>
	<brief_title>An Observational Study MabThera/Rituxan ( Rituximab ) Plus Chemotherapy As First-Line Treatment Patients With Diffuse Large B-Cell Lymphoma Follicular Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Histologically confirm CD20+ diffuse large Bcell lymphoma follicular lymphoma Treatment MabThera/Rituxan per locally approve China package insert Documented patient medical record Previous treatment diffuse large Bcell lymphoma follicular lymphoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>